BR112022025192A2 - Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmo - Google Patents
Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmoInfo
- Publication number
- BR112022025192A2 BR112022025192A2 BR112022025192A BR112022025192A BR112022025192A2 BR 112022025192 A2 BR112022025192 A2 BR 112022025192A2 BR 112022025192 A BR112022025192 A BR 112022025192A BR 112022025192 A BR112022025192 A BR 112022025192A BR 112022025192 A2 BR112022025192 A2 BR 112022025192A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivative
- fusion protein
- insulin
- protein
- insulin aspart
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
DERIVADO DE INSULINA ASPARTE, E MÉTODO DE PREPARAÇÃO DO MESMO E USO DO MESMO Um derivado de insulina asparte e um método de preparação do mesmo são revelados. O derivado compreende uma proteína de fuso de uma unidade de dobra de proteína fluorescente verde e um precursor de insulina asparte ou um fragmento ativo do mesmo. O nível de expressão da proteína de fusão é significantemente aumentado, e a proteína de precursor de insulina asparte na proteína de fusão é dobrada corretamente e tem uma atividade biológica. Em adição, a unidade de dobra de proteína fluorescente verde na proteína de fusão pode ser digerida em pequenos fragmentos por uma protease, que tem uma diferença de peso molecular grande comparado à proteína alvo e, então, é fácil de separar. Adicionalmente, é fornecido um método para preparar a insulina asparte e um intermediário por meio do uso da proteína de fusão.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010526819.7A CN113773400B (zh) | 2020-06-09 | 2020-06-09 | 一种门冬胰岛素衍生物及其应用 |
| PCT/CN2021/099244 WO2021249444A1 (zh) | 2020-06-09 | 2021-06-09 | 一种门冬胰岛素衍生物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112022025192A2 true BR112022025192A2 (pt) | 2023-02-28 |
| BR112022025192A8 BR112022025192A8 (pt) | 2023-03-07 |
Family
ID=78834980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025192A BR112022025192A8 (pt) | 2020-06-09 | 2021-06-09 | Derivado de insulina asparte, e método de preparação para o mesmo e uso do mesmo |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230312668A1 (pt) |
| EP (1) | EP4163376A1 (pt) |
| JP (1) | JP2023528996A (pt) |
| CN (2) | CN113773400B (pt) |
| BR (1) | BR112022025192A8 (pt) |
| WO (1) | WO2021249444A1 (pt) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19735711C2 (de) * | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
| JP3406244B2 (ja) * | 1999-04-30 | 2003-05-12 | 伊藤ハム株式会社 | 新規な融合蛋白質からの組み換えインスリンの製造方法 |
| US20120214963A1 (en) * | 2011-02-23 | 2012-08-23 | Elona Biotechnologies | Aspart proinsulin compositions and methods of producing aspart insulin analogs therefrom |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CN102070717B (zh) * | 2009-11-19 | 2013-04-10 | 东莞太力生物工程有限公司 | 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物 |
| CN101875700B (zh) * | 2010-04-09 | 2012-09-26 | 无锡和邦生物科技有限公司 | 一种增加促胰岛素分泌肽融合蛋白生物活性的方法 |
| CN102504022A (zh) * | 2011-11-30 | 2012-06-20 | 苏州元基生物技术有限公司 | 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法 |
| WO2013142859A2 (en) * | 2012-03-23 | 2013-09-26 | Wuhan Peptech Pharmaceutical Co., Ltd. | Fusion proteins of superfolder green fluorescent protein and use thereof |
| CN105087724B (zh) * | 2014-05-04 | 2019-12-03 | 重庆派金生物科技有限公司 | 酵母重组表达门冬胰岛素的制备方法 |
| DK3227455T3 (da) * | 2014-12-01 | 2023-08-21 | Pfenex Inc | Fusionspartnere til peptidfremstilling |
| JP7175760B2 (ja) * | 2015-09-07 | 2022-11-21 | ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） | 新規なｉｇｆｒ様レセプター及びその使用 |
| CN105418755A (zh) * | 2015-12-28 | 2016-03-23 | 珠海冀百康生物科技有限公司 | 速效胰岛素前体蛋白以及速效胰岛素的制备方法 |
| WO2020051812A1 (zh) * | 2018-09-12 | 2020-03-19 | 美药星（南京）制药有限公司 | 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法 |
-
2020
- 2020-06-09 CN CN202010526819.7A patent/CN113773400B/zh active Active
-
2021
- 2021-06-09 BR BR112022025192A patent/BR112022025192A8/pt unknown
- 2021-06-09 CN CN202180041124.2A patent/CN115768896A/zh active Pending
- 2021-06-09 WO PCT/CN2021/099244 patent/WO2021249444A1/zh unknown
- 2021-06-09 EP EP21821284.3A patent/EP4163376A1/en not_active Withdrawn
- 2021-06-09 US US18/001,254 patent/US20230312668A1/en active Pending
- 2021-06-09 JP JP2022576134A patent/JP2023528996A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113773400B (zh) | 2023-08-18 |
| WO2021249444A1 (zh) | 2021-12-16 |
| CN115768896A (zh) | 2023-03-07 |
| EP4163376A1 (en) | 2023-04-12 |
| CN113773400A (zh) | 2021-12-10 |
| US20230312668A1 (en) | 2023-10-05 |
| BR112022025192A8 (pt) | 2023-03-07 |
| JP2023528996A (ja) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0916668A2 (pt) | composições e métodos para anticorpos direcionados à proteína do complemento c5 | |
| AR088381A1 (es) | Formulaciones de etanercept estabilizadas con meglumina | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| UA111825C2 (uk) | Стабілізований препарат, що містить антитіло проти ngf | |
| BRPI0821004A8 (pt) | Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste | |
| BRPI0516323A (pt) | construtos de rna | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| BR112015014751A8 (pt) | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. | |
| AR095451A1 (es) | Formulación de anticuerpos | |
| BR112015019066A2 (pt) | Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos | |
| BRPI0615292A8 (pt) | composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada | |
| UY29410A1 (es) | Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones. | |
| BR112012024934A2 (pt) | sistemas de ablação de transgene induzida farmacologicamente | |
| BRPI0509182A (pt) | co-cristais de gossipol e uso dos mesmos | |
| NI201000079A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrófilos. | |
| UY30166A1 (es) | Nuevas arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos | |
| AR079197A1 (es) | Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas | |
| BR112014011055A2 (pt) | novos derivados de [1,2,3]triazolo[4,5-d]pirimidina | |
| BRPI0714399B8 (pt) | composição farmacêutica líquida oral | |
| BR0214386A (pt) | Método para identificação de enzimas de objetivação a tumor | |
| BR112014010590A2 (pt) | 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose | |
| BRPI0517792A (pt) | macrolonas - quinolonas amino-substituìdas | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| CL2008002727A1 (es) | Composicion que comprende un polipeptido de glandula salival de anophles gambiae, y metodo de produccion; constructo de polipeptido y contructo de acido nucleico, y metodo de produccion; composicion de vacuna o medicamento y metodo de produccion; uso para tratar o prevenir una enfermedad transmitida por artoropodos | |
| CL2011000135A1 (es) | Uso de una fromulacion farmaceutica acuosa que comprende 0,5-10% de terbinafina o una sal de la misma, 2-10% de un fosfolipido y 1-5% de un surfactante, para preparar un medicamento util para tratar una infeccion fungica; formulacion farmaceutica. |